| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 10-K |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Conference Call and Webcast Today, November 12, 2026, at 4:30 p.m. ET |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
–Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount |
| 20 Aug 2026 |
Form 4: Olukotun Adeoye Y, Director
Sold 2,000 shares ($174K) |
| 20 Aug 2026 |
Form 4: Perry Michael S, Director
Sold 11,600 shares ($1.01M) |
| 18 Aug 2026 | 144 |
| 18 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Conference Call and Webcast Today, August 4, 2026 at 4:30 p.m. ET |
| 04 Aug 2026 | 10-Q |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 17 Jun 2026 |
Form 4: Cohen Matthew Gregory, Director
Received 11,882 shares as a grant or award |
| 17 Jun 2026 |
Form 3: Cohen Matthew Gregory, Director
Holds 0 shares of Common Stock |
| 16 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026. |
| 19 May 2026 | 144/A |
| 19 May 2026 | 144/A |
| 19 May 2026 | 144/A |
| 14 May 2026 |
Form 4: Lu Hongbo, Director
Sold 2,970 shares ($228K) |
Loading...